CLAIMS

1. A method for inducing or modulating T or B cell tolerance to donor cells, tissue or organ in a recipient comprising administering to the recipient a LFA-1 inhibitor in combination with a costimulation inhibitor and/or a mTOR inhibitor.

2. A method for inducing hematopoietic chimerism in a recipient of cells, tissue or organ transplant from a donor comprising administering to the recipient
i) bone marrow cells or other precursor cells from the donor; and
ii) a LFA-1 inhibitor in combination with at least one co-agent selected from a co-stimulation inhibitor and a mTOR inhibitor.

3 A method for treating diabetes comprising administering to a subject in need of such a treatment, in addition to i) and ii) as defined in claim 2,

iii) allogeneic pancreatic islet cells or other insulin producing cells.

4. A method for inducing apoptosis of activated T cells in a subject in need of such treatment, comprising administering to said subject a therapeutically effective amount of a LFA-1 inhibitor in combination with at least one co-agent selected from a co-stimulation inhibitor and a mTOR inhibitor.

5. A method for delaying progression of, attenuating severity of, suppressing, mitigating or treating immune disorders or diseases in a subject by inducing or modulating immune tolerance in said subject, the immune disorders or diseases being dependent on activation of lymphoid cells, which method comprises administering to said subject a therapeutically effective amount of a LFA-1 inhibitor in combination with at least one co-agent selected from a costimulation inhibitor and a mTOR inhibitor.

6. A method for treating malignancies in a subject in need thereof, comprising administering to said subject cells i) and a product ii) as defined in claim 2, in order to achieve full or mixed hematopoietic chimerism.

7. A method for treating non-malignant diseases of bone marrow failure, comprising administering to said subject cells i) and a product ii) as defined in claim 2, in order to achieve full or mixed hematopoietic chimerism.

8. A method according to any preceding claim, further comprising administering to the recipient or subject 15-deoxyspergualine or an immunosuppressive homologue, analogue or derivative thereof.

9. Use of a LFA-1 inhibitor in combination with at least one co-agent selected from a co-stimulation inhibitor and a mTOR inhibitor in a method according to any one of claims 1 to 8.

10. A pharmaceutical combination comprising

a) a LFA-1 inhibitor; and
b) at least one co-agent selected from a costimulation inhibitor and a mTOR inhibitor.

11. A combination according to claim 10 for use in a method according to any one of claims 1 to 8.

12. A combination according to claim 10 or claim 11, further comprising 15-deoxyspergualine or an immunosuppressive homologue, analogue or derivative thereof.